Two New Fillers Are Granted FDA Approval
Galderma, the brand behind fillers like Restylane, Dysport and Sculptra Aesthetic, announced today the FDA approval of two new fillers to the Restylane category: Restylane Refyne and Restylane Defyne. The products are designed to help smooth out smile and laugh lines while maintaining a natural look. The launches also make the third and forth FDA approvals received by the brand’s Aesthetic and Corrective division in just two and a half years.
You May Also Like: The FDA Just Banned This Common Bathroom Item
Unlike other fillers that are already on the market, Restylane Defyne and Restylane Refyne incorporate a special XpresHAn technology, deeming these products as next-generation hyaluronic acid fillers. The technology allows for the product to move within the face as facial expressions are made to prevent a fake, injected or unnatural look.
Both Restylane Refyne and Restylane Defyne are proven to last for up to 12 months. Kelly Huang, VP and general manager of the U.S. Aesthetic and Corrective business for Galderma, said, “We saw an opportunity to address a common concern for patients who have not yet tried a dermal filler by designing gels that provide natural-looking results. With these new brands, the Restylane family of products now represents the broadest offering of HA dermal fillers in the U.S.”
Both Restylane Refyne and Restylane Defyne were originally approved in Europe in 2010 under the name Emervel.